Ramipril has been used in twice daily dose of 5 mg in most heart failure trials, whereas the dose used in Heart Outcomes Prevention Evaluation (HOPE) study was 10 mg once at bedtime. The HOPE investigators in an ambulatory blood pressure (ABP) substudy observed a fall of nighttime but not daytime blood pressure (BP). We examined the effects of once daily ramipril 10 mg versus 5 mg twice a day. Twenty-nine patients were recruited based on the original criteria for the HOPE study and were given ramipril either in twice-daily dose (5 mg b.d.) or once daily (10 mg o.d.) each morning in randomized, prospective crossover trial. Twenty-four hour ABP recordings were taken just before commencement of ramipril therapy and after treatment with twicedaily and once-daily ramipril. Our results show that ramipril causes a significant reduction of BP over 24-h period as compared with baseline. The mean baseline ABP was 124/73 mm Hg, which reduced to 117/69 mm Hg for the twice-a-day regimen (Po0.001) and 115/68 mm Hg for the once a day regimen (Po0.001). Both regimes effectively lower BP to a similar extent. Ramipril causes significant BP reduction in both once-and twice-daily dosing. The fall in BP after daytime dosing is greater than that observed in the HOPE study (including ABP substudy). Once-daily dosing in the morning seems to be effective in causing a significant reduction in the ABP profile of patients at high-risk of a future vascular event.
Introduction
Several studies have shown that angiotensinconverting enzyme (ACE) inhibitors improve survival in patients with left ventricular dysfunction. The Heart Outcomes Prevention Evaluation (HOPE) study, 1 however, showed that in patients aged 55 years or older, with high risk of cardiovascular events and without evidence of left ventricular dysfunction, ramipril significantly reduced the risk of death, myocardial infarction and stroke. The effect was not thought to be due to BP lowering per se as the office blood pressure (OBP) fell by an average of 3/2 mm Hg only. 1 Indeed, the beneficial effects seen in HOPE was calculated to be around three times than that expected of a decrease of BP of that degree. 2 However, more recently even small differences in OBP as observed in the AngloScandinavian Cardiac Outcomes Trial study between different treatment regimes may translate into significant differences in outcome. 3 Therefore, clearer definition of the effect of treatment by studying ambulatory blood pressure (ABP) profile may provide clearer insight into possible benefits of BP lowering.
The parent compound of ramipril has an elimination half-life of 1-5 h in healthy volunteers. 4, 5 Its metabolites have an elimination half-life of 13-17 h with daily doses of 5-10 mg. However, with smaller doses of 1-2 mg, the elimination half-life is longer ranging from 35 to 60 h, and is thought to be due to the binding/dissociation kinetics of the ramiprilat/ ACE complex. The half-life is also significantly increased in the elderly and in the presence of renal impairment. [5] [6] [7] Previous studies on the effects of ramipril in heart failure have shown that ramipril resulted in a reduced mortality. 8 However, the target dose of ramipril used was 5 mg twice daily. In the HOPE study, the benefits observed were deemed out of proportion to the reduction in OBP. However, in a substudy of the HOPE study utilizing 24 h ABP measurement, a significant reduction in 24 h ABP measurement was demonstrated, more pronounced during the night after ramipril was given once daily at bedtime. The authors of this substudy suggested that the beneficial effects of ramipril on cardiovascular morbidity and mortality might be at least partly attributed to BP lowering. 9 ABP monitoring profiles BP over a 24-h period and has been shown to correlate more accurately with target organ damage than clinic mercury sphygmomanometer readings 10 and it provides additional information such as BP load, BP variability and nocturnal BP profile. 11 The objective of this study was to assess the duration of effect of ramipril treatment on the BP in normotensive patients similar to those in the HOPE study when the treatment is administered either once daily in the morning or twice daily. ABP monitoring in these patients may provide evidence of a significant effect on BP due to ramipril therapy that is not reflected by office mercury sphygmomanometer readings and which may have contributed in part to the beneficial effects of ramipril seen in the HOPE study.
Methods

Study participants
Patients were recruited based on the original inclusion and exclusion criterion for the HOPE study. 1 Briefly, people with and without diabetes were recruited, who were aged 55 years or older, and who had a history of cardiovascular disease (coronary artery disease, stroke or peripheral vascular disease) or diabetes plus at least one other cardiovascular risk factor (total cholesterol 45.2 mmol/l, high-density lipoprotein-cholesterol oo0.9 mmol/l, hypertension, known microalbuminuria or current smoking). Key exclusion criteria were dipstick-positive proteinuria or established diabetic nephropathy, other severe renal disease, hyperkalemia, congestive heart failure, low-ejection fraction (o60%), uncontrolled hypertension (all patients had a clinic BP of o160/ 90 mm Hg), recent myocardial infarction or stroke (o4 weeks) and use of or hypersensitivity to vitamin E or ACE inhibitors.
The local research ethics committee based at the Sandwell and West Birmingham approved the study. The study was carried out at a single centre in a prospective crossover trial. Informed consent was obtained from all the patients.
OBP
OBP was recorded by an experienced nurse in the sitting position after 15 min of rest. The BP was checked using an automated OMRON manometer. The same arm was used for OBP and ABP measurements. A variable number of OBP readings were obtained to ensure that patient does not have uncontrolled hypertension. After recruitment a minimum of one BP reading was made as it was recorded to assess patient safety for continuation of trial.
ABP measurement ABP values were obtained using a non-invasive oscillometric system (SpaceLabs 90207, SpaceLabs, Inc). An experienced nurse or a technician fitted the device to the patient. Patients were instructed not to restrict their daily activities during the monitoring periods. BP and heart rates were recorded automatically every 20 min during the daytime (07.00-23.00 h) and at 30 min interval during the night time (23.00-7.00 h). We averaged readings over an hour to give a single hourly reading, therefore reducing the effect of any missing data. Means were calculated for the whole 24-h period and for three 4 h periods between (24:00-15:00 h, 01.00-04.00 h and 05.00 h-08.00 h).
The patients selected were not on any ACEinhibiting medication at the time of recruitment. There was a run-in period of a week. After that, patients were initiated on ramipril 2.5 mg once daily for 1 week and their renal function was subsequently monitored. Patients were subsequently randomised to either 5 mg ramipril in once-daily dose in the morning or 2.5 mg ramipril in twicedaily dose. After a 3-week-period, the dose of ramipril was uptitrated to 10 mg either as a oncedaily dose in the morning, or as a 5 mg twice-daily dose to be given at 10.00 and 22.00 h. Drawing out a card blindly to allocate patients to treatment with once-or twice-daily treatment regimes initially did randomization. Eventually, all of these patients were then crossed over to receive ramipril in the alternative ramipril dose (either 5 mg twice a day or 10 mg once daily in the morning). There was no washout period between the two dosing regimens as we were comparing the same drug in same total dosage and moreover, the ABP recordings were taken 3 weeks after the crossover. Their BP was monitored with a 24-h ABP recording just before commencement of ramipril, week 8 (3 weeks after maximum tolerated dose) and week 11 (3 weeks after crossover) as shown in Table 1 .
Statistics
Power calculations were derived from the study by Coates et al. 12 on ABP monitoring in the assessment of antihypertensive treatment. In a sequential trial for a power of 0.8 (Po0.05), the number of patients needed to detect a difference of 5 mm Hg in systolic blood pressure (SBP) between two treatment groups is 27 for an ABP study. Similarly, for a difference of 3 mm Hg, in diastolic blood pressure (DBP) the number needed for a similar powered trial was 35. 
Results
Thirty-two patients fulfilled the inclusion criteria and after consent were initiated on ramipril therapy. Three patients discontinued owing to adverse reaction to ramipril therapy. Two of them developed dry cough and the third patient reported dizziness on treatment with ramipril. Adequate recordings with 480% recordings were available in 27 out of the 29 subjects studied who were considered for analysis. One out of these 27 patients did not tolerate the top dose of ramipril 10 mg once a day or 5 mg twice a day and his ABP profile was assessed using the dose of 2.5 mg twice a day versus 5 mg once a day. Baseline characteristics of these 27 patients studied are shown in Table 2 and the concomitant medications at the time of randomization are shown in Table 3 . One patient had a reduction in the dose of b-blockers during the course of this study owing to symptomatic bradycardia. All other patients had no adjustment of their antihypertensive therapy during this period. There was a reduction in the ambulatory SBP and DBP profile of these patients when treated with ramipril given either in a 5 mg twice-daily dose or 10 mg once daily in the morning as compared with the baseline ABP (Figures 1 and  2 ). The average SBP was 123.7 mm Hg at baseline and fell to 116.9 mm Hg on the twice-daily dose and 115.1 mm Hg on the once-daily dose (P-values o0.001 for both values). Similarly, the DBP was 73.3 mm Hg at baseline and fell to 69.3 mm Hg on the twice-daily dose and 68.3 mm Hg on the oncedaily dose (P-value o0.001 for both values). There was no difference (P ¼ NS), however, between the once-daily and the twice-daily dosage regimens. We further analysed the difference in the BP profile at 2-6, 15-18 and 19-22 h after ramipril therapy as a reflection of the peak and trough effects of ramipril. These data again showed that there was a significant reduction of ABP with both once-or twice-daily dosages as compared with baseline at each of the different time intervals (Tables 3 and 4 ). There was a trend to better BP control with once-daily dosing as (Tables 2 and 3 ). There was no significant change in either serum potassium or creatinine after treatment with ramipril. The mean pretreatment serum potassium was 4.370.3 mmol/l and after treatment was 4.370.3 mmol/l. The serum creatinine was 87712 and 89715 mmol/l before and after treatment.
Discussion
Our study showed a significant drop in both daytime and nighttime BP when patients were treated with ramipril either in 10 mg daily dose (in the morning) or 5 mg twice daily. The average 24 h BP dropped by 8.6/5.0 mm Hg on treatment with ramipril in 10 mg once-daily dose administered in the morning as compared with 6.8/4.0 mm Hg when treated with 5 mg ramipril twice daily. ABP HOPE substudy showed a significant drop in the night time BP but did not show any difference in the daytime BP probably due to the bed time dosing and the small number of patients studied. 9 The average 24-h BP was reduced by 10.0/6.6 mm Hg in their study, which is comparable to the reduction seen in our study along with a recently published study comparing the effect of treatment with ramipril versus diltiazem on the ABP profile. 13 The fall in OBP was not significant when patients were treated with either once-or twice-daily regime of ramipril. This was in keeping with the small reduction of 3/2 mm Hg in OBP as seen in the HOPE study (Tables 5 and 6 9 and in our study. One might argue that the high baseline OBP in the HOPE substudy would favour a greater fall; our patients had OBP lower than in the main HOPE study.
The rationale to reduce night time pressure in high-risk patients for a future cardiovascular event is supported by several studies, which suggested that an increase in night-to-day ratio of BP leads to an increased risk of cardiovascular events. 16, 17 On the other hand, there are studies that raise serious concerns about further reduction of night-time BP leading to a possible increase in adverse events owing to coronary or cerebral hypoperfusion. [18] [19] [20] The favourable influence of ramipril treatment observed in HOPE study suggests that this was not an important factor in the patients recruited in the HOPE study.
In conclusion, ramipril is effective in lowering BP over a 24-h period when given in either once daily in the morning or twice daily regime and assessed by ABP monitoring. Once-daily treatment is likely to aid compliance, especially in patients who fulfil HOPE study criteria and will typically require number of other medications to reduce cardiovascular risk. The influence of BP reduction that we observed may play a larger role in risk reduction than other investigators have proposed. What is known about the topic? K In the HOPE study, use of the ACE inhibitor ramipril in a dose of 10 mg once daily at night time was associated with a 22% relative risk reduction in cardiovascular death, myocardial infarction or stroke, despite only a modest reduction of 3/2 mm Hg in OBP. K In a subsequent ambulatory substudy of the HOPE study, investigators showed a significant reduction in the night time ABP but not of the daytime BP when treated with ramipril 10 mg once daily to be given at bedtime.
What this study adds? K In a similar group of patients as HOPE study, our ABP study showed a significant reduction of both daytime and night time BP when treated with either ramipril 5 mg twice a day or ramipril 10 mg once a day given in the morning. K The influence of BP lowering with ramipril observed in our study may have played a larger role in risk reduction than other investigators have proposed.
Abbreviations: ABP, ambulatory blood pressure; ACE, angiotensinconverting-enzyme; BP, blood pressure; HOPE, Heart Outcomes Prevention Evaluation study; OBP, office blood pressure.
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